Cargando…
T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins
T-cell receptor mimic (TCRm) antibodies combine the capacity of a T cell to target intracellular antigens with other capacities unique to antibodies. Neoantigens are abnormal proteins that arise as a consequence of somatic mutations. Technological advances promote the development of neoantigen-targe...
Autores principales: | Xu, Yixiang, Salazar, Georgina To’a, Zhang, Ningyan, An, Zhiqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990144/ https://www.ncbi.nlm.nih.gov/pubmed/33928218 http://dx.doi.org/10.1093/abt/tbz001 |
Ejemplares similares
-
The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein
por: Shen, Ying, et al.
Publicado: (2019) -
Antibody therapies for the treatment of COVID-19
por: Ku, Zhiqiang, et al.
Publicado: (2020) -
The 2018 Nobel Prize in Medicine for breakthroughs in targeting immune checkpoint inhibitors: a brief perspective
por: Rios, Adan, et al.
Publicado: (2019) -
Antibody therapies for the prevention and treatment of viral infections
por: Salazar, Georgina, et al.
Publicado: (2017) -
Engineering antibody and protein therapeutics to cross the blood–brain barrier
por: Zhao, Peng, et al.
Publicado: (2022)